title: Warfarin glycosylation invokes a switch from anticoagulant to anticancer activity.
authors.affiliation: Laboratory for Biosynthetic Chemistry, University of Wisconsin National, Cooperative Drug Discovery Group Program, Pharmaceutical Sciences, Division, School of Pharmacy, 777 Highland Avenue, Madison, WI 53705, USA.
authors.forename: Pauline
authors.initials: P
authors.lastname: Peltier-Pain
authors.forename: Shannon C
authors.initials: SC
authors.lastname: Timmons
authors.forename: Agnès
authors.initials: A
authors.lastname: Grandemange
authors.forename: Etienne
authors.initials: E
authors.lastname: Benoit
authors.forename: Jon S
authors.initials: JS
authors.lastname: Thorson
mesh_terms: D000925:Anticoagulants / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000633:toxicity; D045744:Cell Line, Tumor; D004354:Drug Screening Assays, Antitumor; D006027:Glycosides / Q000138:chemical synthesis / Q000737:chemistry / Q000633:toxicity; D006031:Glycosylation; D006801:Humans; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000378:metabolism; D013237:Stereoisomerism; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000633:toxicity
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D006027:Glycosides; D014859:Warfarin; D006899:Mixed Function Oxygenases; D064417:Vitamin K Epoxide Reductases